Arrowhead Pharmaceuticals (ARWR) EBT: 2010-2025
Historic EBT for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $36.1 million.
- Arrowhead Pharmaceuticals' EBT rose 120.90% to $36.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.5 million, marking a year-over-year increase of 108.41%. This contributed to the annual value of $51.5 million for FY2025, which is 108.41% up from last year.
- Latest data reveals that Arrowhead Pharmaceuticals reported EBT of $36.1 million as of Q3 2025, which was up 120.17% from -$179.1 million recorded in Q2 2025.
- Arrowhead Pharmaceuticals' 5-year EBT high stood at $369.6 million for Q1 2025, and its period low was -$179.1 million during Q2 2025.
- Over the past 3 years, Arrowhead Pharmaceuticals' median EBT value was -$127.0 million (recorded in 2024), while the average stood at -$66.0 million.
- In the last 5 years, Arrowhead Pharmaceuticals' EBT plummeted by 366.37% in 2024 and then soared by 391.05% in 2025.
- Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' EBT stood at -$62.9 million in 2021, then surged by 33.53% to -$41.8 million in 2022, then crashed by 231.84% to -$138.7 million in 2023, then decreased by 26.26% to -$175.1 million in 2024, then soared by 120.90% to $36.1 million in 2025.
- Its EBT stands at $36.1 million for Q3 2025, versus -$179.1 million for Q2 2025 and $369.6 million for Q1 2025.